Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 132 participants.

Also called NCT06126380

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06126380
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Brazil, Canada, France, Germany, Spain, United Kingdom (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06126380. Non-randomized; no masking; primary purpose treatment. Start 2023-10-25 (actual); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
Condition
Kidney Transplant Rejection
Intervention (Drug)
AT-1501
Intervention (Drug)
Tacrolimus
Lead sponsor
Eledon Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06126380
Content hash
6ac94a61b7dd0a256e3057fb5e7dfe8e9987ab9b0bdb785de2f9eacfc0d97888